MedTrace Logo

A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)

NCT00240318 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2010-11-19

No results posted yet for this study

Summary

The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries

Conditions

  • Coronary Arteriosclerosis

Interventions

DRUG

Rosuvastatin calcium

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Crestor Medical Sciences Director, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2005-11-30
Completion
2005-11-30

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • France
  • Italy
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00240318 on ClinicalTrials.gov